Home › Research › Biomarkers
Assessing diagnostic performance of plasma biomarkers in Alzheimer's disease versus cognitively unimpaired individuals: P-tau217 emerges as the optimal marker in Chinese cohorts
Wang S, Liu D, Li H, Jia X, Zhou H, Yu W, Li T, Pan L et al.. Frontiers in aging neuroscience, 2025-03-26
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Introduction The Simoa platform is recognized as a highly sensitive tool for detecting blood-based biomarkers of Alzheimer's disease (AD). It is extensively utilized in the diagnosis and identification of AD, with accuracy emerging as a pivotal metric for assessing assay performance, gradually gaining acceptance and application. The primary objective of this study was to assess the diagnostic efficacy of multiple biomarkers in AD using the Simoa platform. The ultimate goal was to identify the optimal diagnostic biomarkers and further investigate their practical application value in the Chinese population. Methods The study comprised two cohorts: cohort I consisted of 151 healthy controls and 90 AD patients, while cohort II was sourced from a Chinese population cohort, encompassing 123 healthy controls and 126 AD patients, utilizing publicly available data. All patients underwent plasma biomarker concentration measurements using the Simoa platform. The specificity, sensitivity, and accuracy of these biomarkers for AD diagnosis were compared to evaluate their diagnostic efficacy. Results The findings revealed that plasma P-tau217 exhibited excellent performance in differentiating AD from healthy controls, with a sensitivity of 95.0%, specificity of 96.0%, and accuracy of 95.7% for AD diagnosis. Conversely, other indicators, including Aβ42, Aβ42/40, T-tau/Aβ42, P-tau217/Aβ42 and P-tau181, demonstrated some diagnostic efficacy but fell short of meeting the diagnostic criteria. Discussion P-tau217 stands out as a highly effective biomarker for distinguishing AD from CUC, exhibiting extensive clinical application potential in the Chinese population. It presents a promising array of clinical prospects for the Chinese population.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Wang, S., Liu, D., Li, H., Jia, X., Zhou, H., Yu, W., et al. (2025). Assessing diagnostic performance of plasma biomarkers in Alzheimer's disease versus cognitively unimpaired individuals: P-tau217 emerges as the optimal marker in Chinese cohorts. Frontiers in aging neuroscience. https://doi.org/10.3389/fnagi.2025.1554805
Vancouver
Wang S, Liu D, Li H, Jia X, Zhou H, Yu W, et al. Assessing diagnostic performance of plasma biomarkers in Alzheimer's disease versus cognitively unimpaired individuals: P-tau217 emerges as the optimal marker in Chinese cohorts. Frontiers in aging neuroscience. 2025. doi:10.3389/fnagi.2025.1554805. PMID: 40207045.
BibTeX
@article{wang2025-40207045,
author = {Wang, S. and Liu, D. and Li, H. and Jia, X. and Zhou, H. and Yu, W. and Li, T. and Pan, L. and others},
title = {{Assessing diagnostic performance of plasma biomarkers in Alzheimer's disease versus cognitively unimpaired individuals: P-tau217 emerges as the optimal marker in Chinese cohorts}},
journal = {Frontiers in aging neuroscience},
year = {2025},
doi = {10.3389/fnagi.2025.1554805},
pmid = {40207045},
url = {https://doi.org/10.3389/fnagi.2025.1554805}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The specificity, sensitivity, and accuracy of these biomarkers for AD diagnosis were compared to evaluate their diagnostic efficacy.
- Results The findings revealed that plasma P-tau217 exhibited excellent performance in differentiating AD from healthy controls, with a sensitivity of 95.0%, specificity of 96.0%, and accuracy of 95.7% for AD diagnosis.
- Conversely, other indicators, including Aβ42, Aβ42/40, T-tau/Aβ42, P-tau217/Aβ42 and P-tau181, demonstrated some diagnostic efficacy but fell short of meeting the diagnostic criteria.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Effect size95.0%; 96.0%; 95.7%
- Evidence strengthModerate
How this study scored 52/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 30 of the 58 points we could judge it on, which is 52 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Frontiers in aging neuroscience) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40207045) |
| Free to read | 2 / 2 | Free to read |
| Points | 30 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 30 of the 58 points we could judge it on is 52 out of 100. |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “chinese-cohort”
3 studies in the library carry the topic tag “chinese-cohort”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 3 tagged studies.